ICICI Prudential Healthcare Fund vs Nippon India Pharma Fund
ICICI Prudential Healthcare Fund and Nippon India Pharma Fund are both Pharma & Healthcare Funds. As of 6 Nov 2026 (Direct plan, Growth option): 3-year CAGR +22.80% vs +19.00%, 5-year CAGR +17.33% vs +14.80%, volatility 15.33% vs 13.83%, maximum drawdown −20.58% vs −24.02%. Their portfolios overlap by 54.2% (20 stocks held by both).
Showing the Direct plan, Growth option. Portfolio, sector and market-cap figures are the same for every plan and option of a fund.
Key facts
| ICICI Prudential Healthcare | Nippon India Pharma | |
|---|---|---|
| Fund house | ICICI Prudential Mutual Fund | Nippon India Mutual Fund |
| Compared as | Pharma & Healthcare Funds | Pharma & Healthcare Funds |
| NAV | ₹47.3700 | ₹646.8090 |
| NAV date | 6 Nov 2026 | 6 Nov 2026 |
| Launched (first NAV) | 16 Jul 2018 | 2 Jan 2013 |
| Track record | 8.3 yrs | 13.8 yrs |
| Fund size (AUM) | ₹6,861 Cr | ₹9,166 Cr |
| Securities held | 39 | 36 |
| Portfolio as of | 30 Sep 2026 | 30 Sep 2026 |
| Fund page | Full record → | Full record → |
Returns
| ICICI Prudential Healthcare | Nippon India Pharma | |
|---|---|---|
| 1 month | +3.36% | +3.42% |
| 3 months | −0.82% | +0.75% |
| 6 months | +5.24% | +7.20% |
| 1 year | +9.35% | +12.68% |
| 3 years (CAGR) | +22.80% | +19.00% |
| 5 years (CAGR) | +17.33% | +14.80% |
| 7 years (CAGR) | +24.39% | +22.37% |
| 10 years (CAGR) | — | +16.20% |
| Since launch (CAGR) | +20.73% | +17.44% |
| SIP return (XIRR, 5 years) ⓘ | +19.86% | +17.27% |
Up to one year: absolute return. Beyond one year: CAGR. Computed from each fund's own NAV history (AMFI), measured to the latest NAV.
Calendar-year returns
| ICICI Prudential Healthcare | Nippon India Pharma | |
|---|---|---|
| 2026 (year to date) | +10.03% | +13.51% |
| 2025 | +0.05% | −2.46% |
| 2024 | +49.36% | +35.26% |
| 2023 | +42.55% | +40.36% |
| 2022 | −7.63% | −9.06% |
| 2021 | +19.30% | +25.12% |
Risk
| ICICI Prudential Healthcare | Nippon India Pharma | |
|---|---|---|
| Volatility (annualised) ⓘ | 15.33% | 13.83% |
| Downside volatility ⓘ | 9.43% | 8.97% |
| Sharpe ratio ⓘ | 1.06 | 0.90 |
| Sortino ratio ⓘ | 1.73 | 1.39 |
| Maximum drawdown ⓘ | −20.58% | −24.02% |
| Recovery from that fall | 1 months | 15 months |
| Current fall from peak | −1.56% | −1.04% |
| Rolling 1-year return: worst | −12.32% | −15.12% |
| Rolling 1-year return: median | +18.67% | +13.10% |
| Rolling 1-year return: best | +94.27% | +90.70% |
| Share of 1-year periods with a loss | 17.98% | 23.32% |
Against each fund's benchmark
| ICICI Prudential Healthcare | Nippon India Pharma | |
|---|---|---|
| Beta ⓘ | 0.79 | 0.69 |
| Alpha (Jensen's, annualised) ⓘ | +11.69% | +8.81% |
| R² ⓘ | 59.17 | 52.49 |
| Upside capture | 115.18% | 104.96% |
| Downside capture | 54.85% | 59.42% |
| Tracking error | 10.82% | 11.35% |
| Information ratio | 1.14 | 0.75 |
| Treynor ratio | 20.14 | 17.79 |
Portfolio
Asset mix
| ICICI Prudential Healthcare | Nippon India Pharma | |
|---|---|---|
| Equity | 98.91% | 97.31% |
| Cash & equivalents | 1.10% | 2.69% |
Market-cap split (share of fund assets)
| ICICI Prudential Healthcare | Nippon India Pharma | |
|---|---|---|
| Large Cap | 23.35% | 29.71% |
| Mid Cap | 31.98% | 39.02% |
| Small Cap | 42.70% | 28.04% |
| Unclassified | 0.87% | 0.54% |
Concentration
| ICICI Prudential Healthcare | Nippon India Pharma | |
|---|---|---|
| Top 10 holdings | 57.84% | 56.35% |
| Effective number of stocks ⓘ | 21.2 | 22.1 |
| Securities held | 39 | 36 |
Portfolio overlap: 54.2%
20 companies are held by both funds; by weight, 54.2% of the two portfolios is the same. That is a high overlap: holding both adds little diversification beyond holding one.
| Held by both | ICICI Prudential Healthcare | Nippon India Pharma |
|---|---|---|
| Sun Pharmaceutical Industries Limited | 11.49% | 11.71% |
| Cipla Limited | 5.79% | 6.01% |
| Dr. Reddy's Laboratories Limited | 9.73% | 5.45% |
| Mankind Pharma Limited | 5.04% | 4.38% |
| Divi's Laboratories Limited | 3.78% | 7.10% |
| Max Healthcare Institute Limited | 2.63% | 2.70% |
| MedPlus Health Services Limited | 4.31% | 2.53% |
| Abbott India Limited | 2.54% | 2.32% |
| Apollo Hospitals Enterprise Limited | 2.30% | 4.89% |
| Gland Pharma Limited | 1.97% | 2.53% |
| Lupin Limited | 1.88% | 6.17% |
| Alkem Laboratories Limited | 4.82% | 1.82% |
| Syngene International Limited | 3.50% | 1.40% |
| Pfizer Limited | 2.42% | 1.35% |
| Akums Drugs and Pharmaceuticals Limited | 1.92% | 1.21% |
Top 10 holdings
ICICI Prudential Healthcare
- Sun Pharmaceutical Industries Limited11.49%
- Dr. Reddy's Laboratories Limited9.73%
- Cipla Limited5.79%
- Biocon Ltd.5.33%
- Mankind Pharma Limited5.04%
- Alkem Laboratories Limited4.81%
- MedPlus Health Services Limited4.31%
- Cohance Lifesciences Limited4.06%
- Divi's Laboratories Limited3.78%
- Syngene International Limited3.50%
Nippon India Pharma
- Sun Pharmaceutical Industries Limited11.71%
- Divi's Laboratories Limited7.10%
- Lupin Limited6.17%
- Cipla Limited6.01%
- Dr. Reddy's Laboratories Limited5.45%
- Apollo Hospitals Enterprise Limited4.89%
- Mankind Pharma Limited4.38%
- Sai Life Sciences Limited3.92%
- Ajanta Pharma Limited3.61%
- GlaxoSmithKline Pharmaceuticals Limited3.11%
Sector exposure
| ICICI Prudential Healthcare | Nippon India Pharma | |
|---|---|---|
| Pharmaceuticals & Biotechnology | 72.63% | 73.97% |
| Healthcare Services | 18.28% | 20.27% |
| Retailing | 5.05% | 2.53% |
| Chemicals & Petrochemicals | 1.21% | 0.00% |
| Insurance | 1.06% | 0.00% |
| Healthcare Equipment & Supplies | 0.68% | 0.54% |
Questions people ask
What is the difference between ICICI Prudential Healthcare and Nippon India Pharma returns?
As of 6 Nov 2026, Direct plan Growth option: 1-year return +9.35% vs +12.68%; 3-year CAGR +22.80% vs +19.00%; 5-year CAGR +17.33% vs +14.80%; 10-year CAGR — vs +16.20%. Past returns do not indicate future returns.
How do ICICI Prudential Healthcare and Nippon India Pharma compare on risk?
Volatility (36 monthly returns, annualised) 15.33% vs 13.83%; Sharpe ratio 1.06 vs 0.90; Sortino ratio 1.73 vs 1.39; maximum drawdown −20.58% vs −24.02%; beta 0.79 vs 0.69.
How much do ICICI Prudential Healthcare and Nippon India Pharma overlap?
By weight, 54.2% of the two portfolios is invested in the same companies; 20 stocks are held by both, the largest shared positions being Sun Pharmaceutical Industries Limited, Cipla Limited, Dr. Reddy's Laboratories Limited. Based on the portfolios disclosed for Sep 2026 and Sep 2026.
What is the large, mid and small cap split of ICICI Prudential Healthcare and Nippon India Pharma?
ICICI Prudential Healthcare: large cap 23.4%, mid cap 32.0%, small cap 42.7%. Nippon India Pharma: large cap 29.7%, mid cap 39.0%, small cap 28.0% (share of the fund's assets, from its latest disclosed portfolio).
Is this a recommendation to choose one of these funds?
No. This page places the published figures of both funds side by side. It does not rank, rate or recommend either fund; which one suits an investor depends on their goals, horizon and risk tolerance.
More comparisons
ICICI Prudential Healthcare vs
- ICICI Prudential Healthcare vs Aditya Birla Sun Life Pharma and Healthcare
- ICICI Prudential Healthcare vs ITI Pharma and Healthcare
- ICICI Prudential Healthcare vs Tata India Pharma & Healthcare
- ICICI Prudential Healthcare vs DSP Healthcare
- ICICI Prudential Healthcare vs PGIM India Healthcare
- ICICI Prudential Healthcare vs Bajaj Finserv Healthcare
All Pharma & Healthcare Funds comparisons → · Compare up to six funds yourself → · Every fund in this category → · All comparisons →
Sources: NAV from AMFI; returns, risk and ratios computed by MF Analyser from each fund's NAV history (risk on 36 monthly returns, risk-free rate 6.5%); benchmark ratios against each fund's benchmark total-return index; portfolios from each fund house's monthly disclosure. Returns and ratios as of 6 Nov 2026. IDCW options show no return or risk figures because payouts reduce the NAV and AMFI's file carries no payout history to add back. This page compares published figures only — it does not rank, rate or recommend either fund. Past performance does not indicate future returns; mutual fund investments are subject to market risks.